We have a diversified and balanced portfolio covering multiple therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.

         

Compound

Mechanism of action

Target indication

Status

More Information

PIVLAZ®
(clazosentan)

Endothelin receptor antagonist

Cerebral vasospasm associated with
aneurysmal subarachnoid hemorrhage

Commercially available in Japan

  

QUVIVIQ™   (daridorexant)

Dual orexin receptor antagonist

Insomnia

Commercially available in the US and the first countries in Europe;
approved in the UK and Switzerland;
under review in Canada;
Phase 3 in Japan successful – filing expected in H2 2023;
Phase 2 in pediatric insomnia recruiting

Investor webcast

Aprocitentan*

Dual endothelin receptor antagonist

Difficult-to-control (resistant) hypertension

NDA submitted in the US, MAA submitted in the EU, other filings in preparation

Investor webcast

Lucerastat

Glucosylceramide synthase inhibitor

Fabry disease

Phase 3 primary endpoint not met, Open Label Extension study (OLE) ongoing

  

Selatogrel

P2Y12 inhibitor

Suspected acute myocardial infarction

Phase 3 recruiting

Investor webcast

Cenerimod

S1P1 receptor modulator

Systemic lupus erythematosus

Phase 3 recruiting

 Investor webcast

ACT-1004-1239

ACKR3 / CXCR7 antagonist

Multiple sclerosis and other demyelinating diseases

Phase 2 in preparation

  

Sinbaglustat

GBA2/GCS inhibitor

Rare lysosomal storage disorders

Phase 1 complete

  

ACT-1014-6470

C5aR1 antagonist

Immune-mediated disorders

Phase 1

  

ACT-777991

CXCR3 antagonist

Recent-onset Type 1 diabetes

Phase 1

  

IDOR-1117-2520

Undisclosed

Immune-mediated disorders

Phase 1

  


* In collaboration with Janssen Biotech to jointly develop aprocitentan, Janssen Biotech has sole commercialization rights worldwide

Neurocrine Biosciences has a global license to develop and commercialize ACT-709478 (NBI-827104), Idorsia's novel T-type calcium channel blocker. ACT-709478 was investigated in a Phase 2 study for the treatment of a rare form of pediatric epilepsy. The study did not meet the primary endpoint. ACT-709478 was generally well tolerated. Neurocrine continues to analyze the data generated in the study.

 

Innovation fact sheet

For investors, we provide more information on how Idorsia is innovating to change treatment paradigms in our innovation fact sheet. Please visit the investor section for more information.

"My team encourages me to develop and discuss new ideas."

Senior Research Associate, Biology